Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia

NCT07297550 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Severe Aplastic Anemia
Refractory Aplastic Anemia
Newly Diagnosed Aplastic Anemia

Interventions

DRUG: Golidocitinib Capsules

Sponsor

Institute of Hematology & Blood Diseases Hospital, China